Is Galectin Therapeutics Inc (NASDAQ:GALT) a Buy? The Stock Reported more Sellers

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

Investors sentiment increased to 2.15 in Q1 2019. Its up 1.09, from 1.06 in 2018Q4. It is positive, as 3 investors sold Galectin Therapeutics, Inc. shares while 10 reduced holdings. 17 funds opened positions while 11 raised stakes. 6.26 million shares or 31.05% more from 4.77 million shares in 2018Q4 were reported.
Millennium Management Limited Liability Company reported 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Neuberger Berman Grp Inc Limited Liability Company holds 82,494 shares. California Pub Employees Retirement System stated it has 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). 279,748 are held by Geode Cap Mngmt Ltd Liability Corp. State Bank Of America De invested in 0% or 22,029 shares. Barclays Public Limited Company reported 132,391 shares. Goldman Sachs Group Inc holds 174,391 shares. The Illinois-based Citadel Advisors Lc has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Royal Financial Bank Of Canada has 1,100 shares. Moreover, Blackrock has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Cambridge Research Advsr Inc reported 176,222 shares or 0.01% of all its holdings. Vanguard Group Inc Inc accumulated 1.61M shares. Thrivent Financial For Lutherans holds 0% or 15,178 shares in its portfolio. State Street holds 0% or 98,403 shares. Jpmorgan Chase stated it has 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT).

Since April 5, 2019, it had 10 insider buys, and 0 sales for $20.44 million activity. $79,514 worth of stock was bought by OMENN GILBERT S on Friday, May 31. 9,136 shares valued at $39,102 were bought by FREEMAN KEVIN D on Friday, May 31. LEWIS JOEL bought $3,214 worth of stock. The insider CALLICUTT JACK W bought 2,354 shares worth $10,075. The insider ELDRED KARY bought 3,033 shares worth $12,981.

The stock of Galectin Therapeutics Inc (NASDAQ:GALT) registered an increase of 2.23% in short interest. GALT’s total short interest was 3.80M shares in August as published by FINRA. Its up 2.23% from 3.71M shares, reported previously. With 408,100 shares average volume, it will take short sellers 9 days to cover their GALT’s short positions. The short interest to Galectin Therapeutics Inc’s float is 11.04%.

The stock decreased 0.60% or $0.02 during the last trading session, reaching $3.33. About 445,559 shares traded or 28.71% up from the average. Galectin Therapeutics, Inc. (NASDAQ:GALT) has declined 25.70% since August 15, 2018 and is downtrending. It has underperformed by 25.70% the S&P500.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $188.58 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 2 analysts covering Galectin Therapeutics (NASDAQ:GALT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Galectin Therapeutics has $11 highest and $11 lowest target. $11’s average target is 230.33% above currents $3.33 stock price. Galectin Therapeutics had 4 analyst reports since February 23, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, March 7 by H.C. Wainwright. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Buy” rating by FBR Capital on Thursday, March 7.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Seekingalpha.com which released: “Galectin Therapeutics And Belapectin In Phase 3 NASH Cirrhosis: Moving Up – Seeking Alpha” on April 11, 2019, also Seekingalpha.com with their article: “Galectin In NASH, And The Market Assessment – Seeking Alpha” published on March 15, 2019, Seekingalpha.com published: “Galectin holders file to offer up to 1.7M shares – Seeking Alpha” on August 09, 2019. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: Seekingalpha.com and their article: “Update On Galectin Therapeutics’ Potential Entry Into Cancer Market – Seeking Alpha” published on February 15, 2018 as well as Seekingalpha.com‘s news article titled: “Galectin Therapeutics (GALT) Presents At H.C. Wainwright & Co. Annual Global Life Sciences Conference – Slideshow – Seeking Alpha” with publication date: April 09, 2019.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.